Tevogen Bio Holdings, Inc. (TVGN)
7.31
-0.44
(-5.74%)
USD |
NASDAQ |
Mar 06, 16:00
7.20
-0.11
(-1.50%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 29.59M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -86.71% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -0.9623 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | -- |
Profile
| Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ. |
| URL | http://www.tevogen.com |
| Investor Relations URL | https://tevogen.com/investors/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. It focuses on its product, ExacTcell, a technology that treats acute viral infections, long-term consequences of viral infections, and viral and non-viral induced cancers. The company was founded in April 2021 and is headquartered in Warren, NJ. |
| URL | http://www.tevogen.com |
| Investor Relations URL | https://tevogen.com/investors/ |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 14, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |